

## INDEX

### A

- Absenteeism, 89
- Abstinence duration
  - atherosclerosis severity, 199–200
  - bladder cancer, 164
  - cerebrovascular disease, 252–258
  - COPD mortality, 345
  - classifying smoking status, 26–27
  - CHD mortality, 205–215, 223
  - disease development, 129
  - educational attainment, 606–608
  - laryngeal cancer, 131–132
  - locus of control, 542
  - lung cancer diagnosis, 129–131
  - lung cancer risk patterns, 110–122, 122–126
  - multistage models, 126–128
  - MI risk, 203–204
  - overall mortality, 78–80
  - relapse, 23–24, 595–598
  - respiratory symptoms, 303
  - self-efficacy, 541
  - smoking continuum, 606–607
  - withdrawal symptoms, 529–530
- Abstinence
  - long-term, 595–598
  - performance, 525–526
- Age at cessation, lung cancer, 125–126
- Age factors
  - abstinence duration, 606–608
  - airway responsiveness, 338–340
  - cerebrovascular disease, 251
  - CHD mortality, 215–216, 223
  - FEV<sub>1</sub> decline, 329–333
  - menopause, 396–400
  - overall mortality, 80
  - quit ratio, 593–594
  - respiratory symptoms, 286, 288–296
  - smoking and cessation during
    - pregnancy, 390–393
    - smoking continuum, 599–608
- Airway histopathology, former smokers, 108–109
- Airway responsiveness
  - age factors, 338–340
  - clinical studies, 340–341
  - cross-sectional studies, 338–339
  - longitudinal studies, 339–340
  - mechanisms, 338
  - smoking and cessation, 337–341
- Airways obstruction, see FEV<sub>1</sub>
- Alcohol consumption
  - cessation, 524–525
  - esophageal cancer, 152–155
  - former smokers, 556–559
  - hepatocellular cancer, 176
  - laryngeal cancer, 132

oral cancer, 151–152  
pancreatic cancer, 155–159  
American Cancer Society Cancer  
Prevention Study-I, 26, 48–49,  
75–78, 110, 124, 128, 250, 308,  
432, 595–596  
American Cancer Society Cancer  
Prevention Study-II, 48, 78–79,  
110, 124, 129, 132, 159, 172,  
215, 241, 245, 250, 252, 258,  
308, 345  
Anal cancer, 172–176  
Analytic issues of consequence  
assessment, 55–57  
Anxiety, 533–541  
Aortic aneurysm, 241  
Arrhythmias, 195  
Arteriosclerosis obliterans, 244  
Assessing smoking cessation, see  
Chapter 2  
Asthma (see also Airway  
responsiveness)  
nosology, 279–280  
respiratory symptoms, 286  
Atherosclerosis  
CHD development, 191–193  
severity, 199–200  
Attributable risk, pregnancy outcome,  
393–395

## B

Behavioral consequences of cessation,  
see Chapter 11  
Behavioral measures, 25–31  
Bias, 46, 48, 52–55  
Biochemical markers, 33–37  
Birthweight  
cessation after conception, 383–387

cessation before conception,  
382–383  
continued smoking, 381–382  
low, attributable risk, 393–395  
smoking and cessation, 379–387  
Bladder cancer, 159–165  
Blood oxygen delivery, CHD  
development, 195–196  
Body fat distribution, 495  
Body weight, see Chapter 10  
Bogus pipeline, 37  
Bone loss, see Osteoporosis  
Bone mineral content, 444–449  
Breast cancer, 169  
Breathlessness, see Respiratory  
symptoms  
British Physicians Study, 79, 110, 128,  
205, 308, 341  
Bronchitis (see also Respiratory  
infections)  
mortality, 342–345  
nosology, 279

## C

Caffeine use, cessation, 524–525  
Cancers, nonrespiratory, see Chapter 5;  
see also specific sites  
Cancers, respiratory, see Chapter 4; see  
also specific sites  
Carbon monoxide, 34–35  
Cardiovascular disease risk, estimated  
cessation effects, 197  
Cardiovascular diseases, see Chapter 6  
Carotid artery plaques, 246  
Case-control study design, 49–50  
Cerebral blood flow, 246, 251  
Cerebrovascular disease  
abstinence duration, 252–258

- age factors, 251
  - case-control studies, 246–249
  - cross-sectional studies, 246
  - development, 196
  - intervention studies, 251
  - oral contraceptives, 258–260
  - prospective cohort studies, 249–250
  - smoking and cessation, 245–260
  - smoking history, 251–252
  - summary of observational studies, 251
  - Cervical cancer, 165–169
  - Cessation
    - consequences assessment, 46–57
    - process and behavior assessment, 22–46
    - rate, see Quit ratio
    - stage model, 22–24
    - time trends, pregnancy, 393
    - timing, birthweight, 382–386
  - Chapter conclusions, 9–14
  - Chronic obstructive pulmonary disease
    - FEV<sub>1</sub> decline, 328–333
    - mortality, 341–348
    - nosology, 279–285
    - patients, 345–348
  - Cigar smoking
    - as cigarette replacement, 555–556
    - lung cancer, 124–125
    - trends, 593
  - Cigarette consumption
    - bladder cancer, 164
    - cerebrovascular disease, 251–252
    - FEV<sub>1</sub> decline, 329–333
    - laryngeal cancer, 132
    - lung cancer, 124
    - MI risk, 203
    - oral cancer, 151–152
    - overall mortality, 78–80, 86
    - pancreatic cancer, 155
    - pregnancy, 390–393
    - weight gain, 501–502
  - Cohort study design, 48–49
  - Conclusions
    - chapter, 9–14
    - volume, 8
  - Contextual issues, biochemical assessment, 37–46
  - Coping skills, 543–544
  - Coronary artery spasm, CHD development, 195
  - Coronary heart disease (CHD)
    - cross-sectional studies, 199–200
    - cessation, 197–240
    - development, 191–196
    - mortality, 205–224, 227–229
    - patients, 229–239
    - risk factors, 497–499
  - Cotinine, 36–37
  - Cough, see Respiratory symptoms
  - Craving, 523–524
  - Cross-sectional study design, 47–48
- D**
- D-fenfluramine, weight control, 503–504
  - Demographic factors
    - pregnancy outcomes, attributable risk, 393–395
    - smoking and cessation during pregnancy, 390–393
  - Depression, 533–541
  - Diabetics, CHD mortality, 221–222
  - Diet, 500–502
  - Dietary changes, 484–486
  - Dietary practices, 554–555

Diffusing capacity, former smokers, 327–328  
Disease development, abstinence duration, 129  
DNA adduct levels, 109–110  
Duodenal ulcers (see also Peptic ulcers)  
  healing, 432–433  
  recurrence, 433–439  
Duration of abstinence, see Abstinence duration  
Dyspnea, see Respiratory symptoms

## E

Ecologic study design, 47  
Ectopic pregnancy, 375–376  
Educational attainment  
  abstinence duration, 606–608  
  quit ratio, 595  
  smoking continuum, 599–608  
Emphysema  
  mortality, 342–345  
  nosology, 279  
Endometrial cancer, 169–172  
Energy expenditure, 487–490  
Enhancement models, performance, 525–526  
Esophageal cancer, 152–155  
Estrogen metabolism  
  osteoporotic fractures, 443–444  
  premature menopause, 398  
Ethnic factors  
  abstinence duration, 606–608  
  quit ratio, 593  
  smoking and cessation during pregnancy, 391–393  
  smoking continuum, 599–608  
Ex-smokers, see Former smokers

## F

Fertility  
  female, 372, 374–375  
  male, 404–409  
Fetal growth, 373, 379–387; see also Birthweight  
Fetal mortality, 376–379  
Forced expiratory volume in 1 second (FEV<sub>1</sub>)  
  cross-sectional population studies, 308–316  
  decline, 328–337, 345–347  
  longitudinal population studies, 328–337  
Fibrinogens, former smokers, 194  
Food intake, 484–486  
Former smokers  
  absenteeism, 89  
  anal cancer, 172–176  
  atherosclerosis severity, 199–200  
  bladder cancer, 164  
  breast cancer, 169  
  cerebrovascular disease, 246–260  
  cervical cancer, 166–169  
  dietary practices, 554–555  
  diffusing capacity, 327–328  
  early menopause risk, 398–400  
  endometrial cancer, 169–172  
  esophageal cancer, 152–155  
  established COPD, 345–348  
  fibrinogen levels, 194  
  health practices, 546–561  
  health screening, 561–564  
  health status, 87–91  
  hepatocellular cancer, 176  
  HDL-C levels, 192–193  
  kidney cancer, 172

leukemia, 176  
lung cancer risk patterns, 110–122  
medical care utilization, 87  
MI survival, 200–224  
oral cancer, 147–152  
ovarian cancer, 172  
overall mortality, 78–80  
penile cancer, 172–176  
physical activity, 551–554  
population percentage, 585  
pulmonary function, 308–337  
respiratory symptoms, 285–305  
stomach cancer, 176  
Fractures, *see* Osteoporosis  
Framingham Heart Study, 80,  
218–221, 230–235, 250, 258,  
453, 497–498  
Frequency issues, self-reports, 27–28

## G

Gastric secretion, smoking, 429–430  
Gastric ulcers (*see also* Peptic ulcers)  
healing, 440  
recurrence, 440–441  
Gastrointestinal physiology, smoking,  
429–430  
Gender factors  
abstinence duration, 606–608  
alcohol consumption, 556–559  
bladder cancer, 164  
diet, 485–486  
dietary practices, 554–555  
esophageal cancer, 152–155  
MI survival, 237  
oral cancer, 147  
overall mortality, 80  
pancreatic cancer, 155  
physical activity, 551–554

pipe or cigar smoking, 555–556  
postcessation weight gain, 473–483  
quit ratio, 588–593  
respiratory symptoms, 288–296,  
303–304  
smoking continuum, 599–608  
Gestational duration, 379–387; *see also*  
Birthweight

## H

Health practices, former smokers,  
546–561  
Health risk changes, 497–500  
Health screening, former smokers,  
561–564  
Health status, 87–91  
Hemorrhagic stroke, *see*  
Cerebrovascular disease  
Hepatocellular cancer, 176  
High-density lipoprotein cholesterol  
(HDL-C) levels, former smokers,  
192–193  
Hormones, male reproduction, 401

## I

Immune system, respiratory infections,  
305–308  
Impotence, male, 402–404  
Infertility  
female, 372, 374–375  
male, 405–409  
Influenza, *see* Respiratory infections  
Inhalation practices, lung cancer, 124  
Intention to smoke, 588, 608–609  
Intermittent claudication, 243–244  
Interpersonal interactions, 545–546  
Intervention trials, study design, 50–51  
Interviews, 25–29

Ischemic stroke, see Cerebrovascular disease

## K

Kidney cancer, 172

## L

Laryngeal cancer, 131–132

Leukemia, 176

Locus of control, 542–543

Long-term psychological and behavioral consequences and correlates, 532–546

Lung cancer

abstinence duration, 110–122,

122–126, 126–128

age at cessation, 125–126

airway histopathology, 108–109

smoking and cessation, 107–131

cigar smokers, 125

cigarette consumption, 124

DNA adduct levels, 109–110

diagnosis, 129–131

inhalation practices, 124

multistage models, 126–128

nonfilter cigarettes, 124–125

pathophysiologic mechanisms of smoking, 107–110

pipe smokers, 125

smoking duration, 122–123

smoking history, 122–126

## M

Major conclusions, 8

Measures of cessation, 22–46

Measures of quitting behavior, 584–588

Medical care utilization, 87

Menopause, premature, 396–400

Metabolic rate, 487–490

Methodologic issues of consequence assessment, 51–57

Methodologies, cessation assessment, see Chapter 2

Misclassification of smoking status, 49, 51, 52–55

Mood, 533–541

Morbidity (see also Chapter 3: specific causes)

peptic ulcers, 431–432

respiratory, 285–308

Mortality (see also Chapter 3: specific causes)

bronchitis, 342–345

COPD, 341–345, 347–348

cohort studies, 75–83

emphysema, 342–345

fetal, neonatal, and perinatal, 374, 376–379

overall, intervention studies, 84–86

peptic ulcers, 432

weight, 491–495

Mouth cancer, see Oral cancer

Multiple health habits, 559–561

Multiple primary cancers, 176–177

Multiple Risk Factor Intervention Trial, 24, 28, 50–51, 53, 86, 227–228, 333–335, 495, 498, 560–561, 595

Multistage models, lung cancer, 126–128

Myocardial infarct (MI) risk

case-control studies, 200–204

cigarette consumption, 203

cohort studies, 205–224

healthy persons, 200–229

intervention trials, 224–229  
MI patients, 229–239  
recurrent, 230–239

## N

National Health and Nutrition  
Examination Survey, 24, 30, 431,  
453, 583–584  
National Health Interview Survey, 25,  
390–391, 547–564, 583–584  
National trends in smoking cessation,  
see Appendix  
Neonatal mortality, 379–381  
Neoplasms, see Cancers; see also  
specific sites  
Nicotine polacrilex gum  
weight control, 502–504  
withdrawal symptoms, 528, 539  
Nicotine withdrawal, 521–532  
Nonbehavioral measures, 31–46  
Nonfilter cigarettes, lung cancer,  
124–125

## O

Obesity, 490–497  
Obstructive airways diseases, see  
Chapter 7  
Occupational factors, respiratory  
symptoms, 296–299  
Oral cancer  
alcohol consumption, 151–152  
cigarette consumption, 151–152  
former smokers, 147–152  
gender factors, 147  
smoking and cessation, 147–152  
Oral contraceptives, cerebrovascular  
disease, 258–260  
Osteoporosis, 443–453

Osteoporotic fractures, 449–453  
Ovarian cancer, 172  
Overweight, adverse medical and  
psychosocial outcomes, 490–497

## P

Pancreatic cancer, 155–159  
Pathophysiologic mechanisms of  
smoking  
cardiovascular diseases, 191–197  
laryngeal cancer, 131  
lung cancer, 107–110  
male reproduction, 400–401  
pregnancy, 371–374  
premature menopause, 396–398  
osteoporosis, 443–444  
respiratory diseases, 279–285  
skin wrinkling, 453–456  
Penile cancer, 172–176  
Peptic ulcer disease, 429–442  
Peptic ulcers  
morbidity, 431–432  
mortality, 432  
Performance, abstinence, 525–526, 530  
Perinatal mortality  
attributable risk, 393–395  
smoking and cessation, 376–379  
Peripheral arterial occlusive disease,  
241–244  
Peripheral artery disease  
development, 196, 243  
prognosis, 243–244  
Phenylpropanolamine, weight control,  
503–504  
Phlegm production, see Respiratory  
symptoms  
Physical activity, 486, 551–554  
Physician advice, 588, 609

Physiologic measures, 32  
Pipe smoking  
    as cigarette replacement, 555–556  
    lung cancer, 124–125  
    trends, 593  
Pneumonia, see Respiratory infections  
Preeclampsia, 387  
Pregnancy  
    complications, 387  
    outcome, 371–395  
    prevalence of smoking and  
        cessation, 390–393  
    time trends in smoking and  
        cessation, 393  
    weight gain, 373  
Prematurity, 386–387  
Preterm delivery, 386–387, 395  
Prevalence of smoking, pregnancy,  
    390–393  
Process of smoking behavior change,  
    22–24  
Psychological effects of cessation, see  
    Chapter 11  
Pulmonary function  
    former smokers, 308–337  
    smoking cessation, 316–328

## Q

Questionnaires, 25–29  
Quit attempts, 606  
Quit ratio  
    age trends, 593–594  
    definition, 585,  
    educational trends, 595  
    gender trends, 588–593  
    racial trends, 593  
Quitting behavior, measures, 584–588

## R

Racial factors, see Ethnic factors  
Recidivism, 595–598; see also Relapse  
Reduction of smoking, pregnancy,  
    387–389  
Relapse, 23–24, 530–531, 595–598  
Report  
    conclusions, 8  
    development, 8–9  
    overview, 5–7  
Reproduction  
    female, 371–400  
    male, 400–409  
Reproduction, see Chapter 8  
Respiratory cancers, see Chapter 4  
Respiratory diseases, see Chapter 7  
Respiratory function tests, see  
    Spirometric parameters: Small  
        airways function  
Respiratory infections, 305–308  
Respiratory morbidity, smoking  
    cessation, 285–308  
Respiratory symptoms  
    abstinence duration, 303  
    asthmatics, 286  
    cessation clinics, 285–287  
    cross-sectional population studies,  
        288–296  
    longitudinal studies, 299–305  
    occupational groups, 296–299  
    reversal, possible mechanisms, 304  
    smoking and cessation, 285–305  
    smoking history, 299–303

## S

Self-efficacy, 541–542  
Self-management skills, 543–544



Self-report measures, 25–29  
 Self-monitoring, 29  
 Sexual activity, male, 401–404  
 Sexual behavior, cervical cancer, 166  
 Shortness of breath, *see* Respiratory symptoms  
 Skin wrinkling, 453–456  
 Small airways function, smoking cessation, 323–327  
 Smoking and cessation surveys, methodology, 583–584  
 Smoking behavior change, 22–24  
 Smoking characteristics, *see* Inhalation practices  
 Smoking continuum  
   abstainers for less than 1 year, 606  
   abstainers for 1 to 4 years, 606–607  
   abstainers for 5 years, 607  
   definition, 585–588  
   smokers never trying to quit, 599  
   smokers quitting for at least 1 day during 12-month period, 606  
 Smoking duration, lung cancer, 122–123  
 Smoking history  
   cerebrovascular disease, 251–252  
   FEV<sub>1</sub>, 308–316, 328–337  
   lung cancer, 122–126, 126–128  
   respiratory symptoms, 299–303  
 Smoking interventions  
   cerebrovascular disease, 251  
   CHD mortality, 224–229  
   overall mortality, 84–86  
   pregnancy, 387–389  
   weight control, 500–502  
 Social support, 545–546  
 Spasm, coronary artery, 195  
 Sperm quality, 404–409  
 Spirometric parameters, smoking cessation, 319–323  
 Spontaneous abortion, 372, 376  
 Statistical considerations, 52  
 Stomach cancer, 176  
 Stress, 533–541  
 Stroke patients, cessation, 260  
 Study design, 46–51  
 Subarachnoid hemorrhage, 249, 250, 258–260  
 Surrogate assessments, 30–31  
 Survival prognosis  
   lung cancer, 129–131  
   MI patients, 230–239

## T

T lymphocytes, 306–307  
 Temporal issues, self-reports, 27–28  
 Terminology, assessment, 33–34  
 Thiocyanate, 35–36  
 Thrombosis, CHD development, 193–195  
 Time trends in smoking and cessation, pregnancy, 393  
 Tobacco consumption, esophageal cancer, 152–154  
 Tracheal mucous velocity, 304

## U

U.S. Veterans Study, 49, 79, 110, 124, 125, 128, 129, 132, 151, 152, 155, 164, 172–176, 217–218, 251–252, 345, 432  
 Ulcer healing and recurrence, 432–441  
 Ulcer occurrence, 429–432  
 Ulcers, *see also* Peptic ulcers: Gastric ulcers; Duodenal ulcers

**V**

Volume conclusions, 8

**W**

Weight control strategies, 500–504

Weight cycling, 492–495

Weight gain (see also Chapter 10)

  pregnancy, 373

  risk and amount, 473–483

  causes, 483–490

Weight, mortality, 491–495

Weight-related health risks, 497–500

Well-being, psychological, 533–541

Wheeze, see Respiratory symptoms

Withdrawal symptoms

  relapse, 530–531

  relief, performance, 525–526

  timecourse, 521, 529–530

  variability, 526–529

Wrinkling, skin, 453–456

